-- 
Roche Says Phase II MS Study Showed Disease Reduction

-- B y   L e i g h   B a l d w i n
-- 
2011-10-20T05:04:33Z

-- http://www.bloomberg.com/news/2011-10-20/roche-says-phase-ii-ms-study-showed-disease-reduction.html
Roche said that a Phase II study
showed its ocrelizumab drug maintained significant reduction in
disease activity for multiple sclerosis patients for almost two
years.  Phase III trials are underway to investigate ocrelizumab in
two forms of MS, the company said in an e-mailed statement.  To contact the editor responsible for this story:
Leigh Baldwin at 
 lbaldwin3@bloomberg.net  